Sensus Healthcare, Inc. (NASDAQ:SRTS) Short Interest Update

Sensus Healthcare, Inc. (NASDAQ:SRTS - Get Free Report) saw a large increase in short interest in December. As of December 15th, there was short interest totalling 583,500 shares, an increase of 20.0% from the November 30th total of 486,100 shares. Approximately 4.4% of the company's stock are short sold. Based on an average daily volume of 174,600 shares, the short-interest ratio is currently 3.3 days.

Sensus Healthcare Trading Down 1.8 %

SRTS stock traded down $0.13 during trading hours on Friday, hitting $7.21. 318,480 shares of the stock traded hands, compared to its average volume of 273,869. The stock has a 50-day simple moving average of $7.61 and a 200 day simple moving average of $6.57. The company has a market cap of $118.16 million, a P/E ratio of 12.65 and a beta of 1.16. Sensus Healthcare has a one year low of $2.36 and a one year high of $9.33.

Institutional Investors Weigh In On Sensus Healthcare

Institutional investors and hedge funds have recently bought and sold shares of the business. Truvestments Capital LLC bought a new stake in shares of Sensus Healthcare in the 3rd quarter worth approximately $32,000. Geode Capital Management LLC increased its holdings in shares of Sensus Healthcare by 8.5% in the third quarter. Geode Capital Management LLC now owns 146,404 shares of the company's stock valued at $849,000 after buying an additional 11,525 shares in the last quarter. Sachetta LLC lifted its position in shares of Sensus Healthcare by 12.9% during the 2nd quarter. Sachetta LLC now owns 118,354 shares of the company's stock valued at $631,000 after acquiring an additional 13,544 shares during the last quarter. XTX Topco Ltd lifted its position in shares of Sensus Healthcare by 76.0% during the 3rd quarter. XTX Topco Ltd now owns 31,530 shares of the company's stock valued at $183,000 after acquiring an additional 13,619 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Sensus Healthcare during the 2nd quarter worth $156,000. 25.30% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Maxim Group raised their price objective on Sensus Healthcare from $12.00 to $14.00 and gave the stock a "buy" rating in a research note on Friday, November 15th. HC Wainwright boosted their price objective on shares of Sensus Healthcare from $10.00 to $11.00 and gave the company a "buy" rating in a research report on Monday, November 18th.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.